title: Tuberculosis vaccine development: Shifting focus amid increasing development challenges.
abstract: A new tuberculosis vaccine is needed to replace or enhance BCG, which induces variable protection against Mycobacterium tuberculosis pulmonary infections in adults. Development of new TB vaccine candidates is severely hampered by the lack of a correlate of immunity, unproven animal models, and limited funding opportunities. One candidate, MVA85A, recently failed to meet its efficacy endpoint goals despite promising early-phase trial data. As a result, some in the field believe we should now shift our focus away from product development and toward a research-oriented approach. Here, we outline our suggestions for this research-oriented strategy including diversification of the candidate pipeline, expanding measurements of immunity, improving pre-clinical animal models, and investing in combination pre-clinical/experimental medicine studies. As with any evolution, this change in strategy comes at a cost but may also represent an opportunity for advancing the field.
authors.affiliation: a Aeras ; Rockville , MD USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Graves
authors.forename: D A
authors.initials: DA
authors.lastname: Hokey
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis; D035843:Biomedical Research / Q000639:trends; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D015415:Biomarkers; D032581:Tuberculosis Vaccines
keywords: BCG; Mtb; T cells; tuberculosis; vaccine development; vaccines